 |
Video: What is a Stock Split?
|
 |
Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor. According to our CYTK split history records, Cytokinetics has had 1 split. | |
 |

Cytokinetics (CYTK) has 1 split in our CYTK split history database. The split for CYTK took place on June 25, 2013. This was a 1 for 6 reverse split, meaning for each 6 shares of CYTK owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split.
When a company such as Cytokinetics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CYTK split history from start to finish, an original position size of 1000 shares would have turned into 166.666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cytokinetics shares, starting with a $10,000 purchase of CYTK, presented on a split-history-adjusted basis factoring in the complete CYTK split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/07/2013 |
|
End date: |
10/04/2023 |
|
Start price/share: |
$6.90 |
|
End price/share: |
$27.05 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
292.03% |
|
Average Annual Total Return: |
14.64% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$39,192.16 |
|
Years: |
10.00 |
|
|
 |
Date |
Ratio |
06/25/2013 | 1 for 6 |
|
 |